Disruptive conditions are typical in non-Western markets. The U.S. industry, thrown into a period of significant change as ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

President Donald Trump in February threatened top pharma leaders, including Eli Lilly CEO David Ricks, with tariffs unless ...

In an interview with former Fox News journalist Megyn Kelly, FDA Commissioner Marty Makary introduced a new mechanism-driven pathway that could be leveraged by rare disease therapies while saying that ...